We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merrimack Gets FDA Orphan Drug Designation for MM-141
Merrimack Gets FDA Orphan Drug Designation for MM-141
November 6, 2014
Merrimack Pharmaceuticals has secured orphan drug designation from the FDA for its investigational drug candidate MM-141 to treat pancreatic cancer. Pharmaceutical Business Review
